Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Sarath.Chandra@globaldata.com

  • Home
  • Author: Sarath.Chandra@globaldata.com

Top 25 global insurers market value up 2.7% QoQ during Q4 2023 amidst heightened risk awareness, reveals GlobalData

Life Insurance Corporation of India and Allstate Corp report 25% growth China Life Insurance and Ping An Insurance Group lose over 15% Berkshire Hathaway maintains top position for the last seven quarters The aggregate market capitalization (MCap) of the top 25 global insurers grew by 2.7% to $2.79 trillion quarter-on-quarter (QoQ) during the fourth quarter […]
Read more

Obesity care needs greater revolution, says GlobalData

Novo Nordisk and Eli Lilly have been dominating the obesity scene in the past year with the approval of their glucagon-like peptide-1 receptor (GLP-1R) agonists Wegovy and Zepbound. Although medicines with other mechanisms of actions are available on the market, GLP-1R agonists seem to have a greater impact on weight loss and the patient’s life. […]
Read more

Predictive maintenance plays crucial role in oil and gas industry, says GlobalData

Maintenance strategies in the oil and gas industry have gradually transformed from their early days in the nineteenth century. To achieve operational longevity, timely maintenance is necessary to prevent expensive repair works and unplanned production outages. Technologies, such as AI, machine learning, and the internet of things (IoT) add enormous value to predictive maintenance strategies, […]
Read more

WEF24 sparks intense social media debate on AI, sustainability and global challenges, reveals GlobalData

At the ongoing 54th World Economic Forum (WEF24) in Davos-Klosters, critical global issues from artificial intelligence (AI) advancements to geopolitical tensions ignited vibrant discussions on the social media platform “X”. Influencers delved into topics like cybersecurity, sustainability, economic challenges, and climate change, highlighting the urgent need for responsible innovation and collaborative solutions in a rapidly […]
Read more

Zosurabalpin may end 50-year antibiotic discovery stalemate against Acinetobacter baumanni, says GlobalData

Zosurabalpin, a novel antibiotic currently in Phase I development by Roche, has recently showed promise in ending a 50-year drought in effective treatment against carbapenem-resistant Acinetobacter Baumanni (CRAB), which is categorized by the World Health Organisation (WHO) as a “priority 1 pathogen.” Demonstrating efficacy in vitro and in mouse models, zosurabalpin targets a critical bacterial […]
Read more

First-in-class Minerval shows promise in patients with advanced brain tumors, says GlobalData

Laminar Pharmaceuticals’ first-in-class autophagy inducer Minerval (LAM561, 2-hydroxyoleic acid (2-OHOA)) has reportedly demonstrated  encouraging activity in the difficult-to-treat malignant braintumor patient population, placing it as a potential candidate for the treatment of glioma and other solid tumor malignancies. With a unique membrane-level targeting approach and encouraging early-stage clinical trial data, Minerval holds potential to address […]
Read more

Startups drive blockchain adoption in Southeast Asia’s gaming sector, says GlobalData

The Southeast Asian digital entertainment scene is undergoing a rapid transformation thanks to the integration of blockchain technology with gaming. Startups are leading this revolution, ensuring asset security, genuine digital ownership, player-centric ecosystems, and innovative gaming experiences. This shift is reshaping the conventional gaming market and elevating player engagement, says GlobalData, a leading data and […]
Read more

China reproductive health devices market to reach $450 million in 2030, forecasts GlobalData

China has been witnessing an increasing demand for various reproductive health tests and devices due to several factors such as a growing population, rising awareness about reproductive health, improving healthcare infrastructure, and changing lifestyles. Against this backdrop, China’s reproductive health devices market is expected to reach $450 million in 2030, forecasts GlobalData, a leading data […]
Read more

GlobalData highlights transformative impact of immersive technologies across sectors

The growing demand for immersive experiences is driving the evolution of advanced platforms and technologies. These innovations are set to transform how people engage with content and their environment, offering captivating virtual worlds and enhancing education, training, and various sectors like healthcare, consumer, retail, automotive, travel & tourism, and gaming, says GlobalData, a leading data […]
Read more

Juniper Networks acquisition will bolster Hewlett Packard Enterprise AI and security offerings, says GlobalData

As global tech companies obsess about artificial intelligence (AI), Hewlett Packard Enterprise’s (HPE) proposed acquisition of Juniper Networks for $14 billion will give HPE a respected AI platform for infrastructure, more security capabilities and a stronger stake in the telecom equipment market, says GlobalData, a leading data and analytics company. Steven Schuchart, Principal Analyst, Enterprise […]
Read more

Rabbit r1 innovative design faces skepticism, yet holds hope for future evolution, finds GlobalData

Rabbit Inc, a Santa Monica-based AI startup, has unveiled a custom-built consumer AI device running on a natural-language operating system “r1” that acts like a walkie-talkie with a camera at the Consumer Electronics Show (CES) 2024. It offers some of the smartphone-free solutions for tasks such as booking flights, ordering meals, and arranging transportation. In […]
Read more

J&J acquisition of Ambrx bolsters cancer ADC portfolio amidst big pharma’s growing investment trend, says GlobalData

Following the news that Johnson & Johnson (J&J) has entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Ambrx Biopharma for $2.0 billion; Israel Stern, MSc,  Oncology & Hematology Analyst at GlobalData, a leading data and analytics company, offers his view: “J&J will have the rights to antibody-drug conjugate (ADC)-focused biotech, which includes anvatabart […]
Read more

Bluebird second reimbursement deal provides valuable advantage for Lyfgenia in upcoming battle for market share, says GlobalData

Following the news that Massachusetts-based biotechnology company bluebird bio Inc (bluebird bio) has signed a second outcomes-based reimbursement deal with a large commercial payer for its sickle cell disease gene therapy, Lyfgenia (lovotibeglogene autotemcel); Nancy Jaser, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Combined with its first coverage […]
Read more
1 … 79 80 81 82 83 … 209